Skip to main content
Clinical Trials/ISRCTN10197225
ISRCTN10197225
Completed
未知

Characterising the effects of exercise on immune cells in blood across the myeloma survivorship continuum

niversity of Bath0 sites23 target enrollmentJuly 8, 2021

Overview

Phase
未知
Intervention
Not specified
Conditions
Multiple myeloma
Sponsor
niversity of Bath
Enrollment
23
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 8, 2021
End Date
September 30, 2023
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Bath

Eligibility Criteria

Inclusion Criteria

  • 1\. A diagnosis of smouldering multiple myeloma who have not received any treatment.
  • 2\. A diagnosis of multiple myeloma who have either: completed their first cycle of induction therapy, or are in remission following a successful haematopoietic stem cell transplant.
  • 3\. Aged 18 years or over.

Exclusion Criteria

  • 1\. World Health Organisation (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status \>1\.
  • 2\. Deemed unsafe to exercise according to the Physical Activity Readiness Questionnaire (PARQ).
  • 3\. Any comorbidity that is likely to progress or be exacerbated over the course of the trial period.
  • 4\. Cognitive impairment deemed a risk by the healthcare team or participation in the trials (e.g. diagnosis of neurodegenerative disease).
  • 5\. Unable to understand explanations and/or provide informed consent.
  • 6\. Any condition and/or behaviour that would pose undue personal risk or introduce bias into the trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials